. "ONO-RS 411"@en . . . . "Seiei Sasatani, Masashi Shiota, Yoshinori Ii, \"Granules containing pranlukast, process for producing the granules, and method of improving adhesiveness of pranlukast.\" U.S. Patent US5876760, issued March, 1995."@en . . . . . . . . . "# Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S: Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma. Drug Metab Pharmacokinet. 2006 Apr;21(2):133-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16702733"@en . "approved"@en . "SID50126316"@en . . . . . "Pranlukast selectively antagonizes leukotriene D₄ (LTD₄) at the cysteinyl leukotriene receptor, CysLT₁, in the human airway. Pranlukast inhibits the actions of LTD₄ at the CysLT₁ receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus."@en . "Pranlukast"@en . "Humans and other mammals"@en . . . . . . . "Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. "@en . . . . . "Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens."@en . . . "103177-37-3"@en . . "Side effects include headache, abdominal or stomach pain, cough, dental pain, dizziness, fever, heartburn, skin rash, stuffy nose, weakness or unusual tiredness."@en . . . " "@en . . . . . . .